Today, a dendritic cell vaccine targeting LMP1 and LMP2 (expressed in NPC) successfully went through a phase II trial of immunotherapy in EBV-positive metastatic NPC patients; however, its effectiveness is restricted [14]. Here, PSMB9 is linked to nasopharyngeal carcinoma.